Burkhard Prause - Bruker President and CEO, BEST
| BRKR Stock | USD 81.26 0.29 0.36% |
CEO
Dr. Burkhard Prause, Ph.D., is resident and Chief Executive Officer, Bruker Energy Supercon Technologies, Inc of the company. Dr. Prause has served as President and Chief Executive Officer of Bruker Energy Supercon Technologies, Inc., or BEST, since April 2008, with responsibility for management of its global operations. Dr. Prause also was a director of BEST from April 2012 to February 2013. Additionally, he has served as a director of Hydrostatic Extrusions Ltd. since April 2013, and as a Managing Director of Bruker EAS GmbH and Bruker HTS GmbH since January 2005, RI Research Instruments GmbH since December 2008, and Bruker ASC GmbH since March 2009. Prior to that time, Dr. Prause served as Product Manager for Bruker BioSpin MRI GmbH. Before joining Bruker BioSpin MRI GmbH in 2002, Dr. Prause was a senior staff scientist at the MaxPlanck Institute in Tubingen, Germany. Dr. Prause currently is a director of CCAS, and from 2006 to 2010, Dr. Prause was Chairman of ivSupra, a German superconductor industry coalition since 2018.
| Age | 57 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 40 Manning Road, Billerica, MA, United States, 01821 |
| Phone | 978 663 3660 |
| Web | https://www.bruker.com |
Burkhard Prause Latest Insider Activity
Tracking and analyzing the buying and selling activities of Burkhard Prause against Bruker stock is an integral part of due diligence when investing in Bruker. Burkhard Prause insider activity provides valuable insight into whether Bruker is net buyers or sellers over its current business cycle. Note, Bruker insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bruker'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Burkhard Prause over two months ago Disposition of 1083 shares by Burkhard Prause of Bruker at 34.02 subject to Rule 16b-3 |
Bruker Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3367 %, meaning that it created $0.3367 on every $100 dollars invested by stockholders. Bruker's management efficiency ratios could be used to measure how well Bruker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bruker's Return On Tangible Assets are relatively stable compared to the past year. As of 04/30/2024, Return On Assets is likely to grow to 0.11, while Return On Capital Employed is likely to drop 0.09. At this time, Bruker's Return On Tangible Assets are relatively stable compared to the past year. As of 04/30/2024, Intangibles To Total Assets is likely to grow to 0.23, while Intangible Assets are likely to drop slightly above 196.5 M.Similar Executives
| Found 8 records | CEO Age | ||
| John Gunn | Inspire Medical Systems | N/A | |
| Patrick Sullivan | Insulet | 65 | |
| Kim Blickenstaff | Tandem Diabetes Care | 65 | |
| Charles Sherwood | Anika Therapeutics | 69 | |
| Tim Herbert | Inspire Medical Systems | N/A | |
| James Hollingshead | Insulet | 61 | |
| Douglas MBA | Shockwave Medical | 59 | |
| Timothy Herbert | Inspire Medical Systems | 61 | |
Management Performance
| Return On Equity | 0.34 | ||||
| Return On Asset | 0.077 |
Bruker Leadership Team
Elected by the shareholders, the Bruker's board of directors comprises two types of representatives: Bruker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bruker. The board's role is to monitor Bruker's management team and ensure that shareholders' interests are well served. Bruker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bruker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Miroslava Minkova, IR Contact Officer | ||
| Gilles Martin, Independent Director | ||
| Marc Kastner, Independent Director | ||
| Collin DSilva, Pres Division | ||
| Anthony Mattacchione, Interim CFO and Sr. VP of Fin. and Accounting | ||
| Falko Busse, President of the Bruker BioSpin Group and Executive Officer of the Company | ||
| Urban Faeh, Pres GmbH | ||
| Michael Knell, Vice President - Finance, Chief Accounting Officer | ||
| Mark Munch, President of Bruker Nano Group | ||
| Brent JD, General Secretary | ||
| Hermann Requardt, Director | ||
| WolfDieter Emmerich, Independent Director | ||
| Juergen Srega, President of Bruker Daltonics Division and President of Bruker Calid Group | ||
| Stephen Fesik, Independent Director | ||
| John Ornell, Director | ||
| Adelene Perkins, Independent Director | ||
| Cynthia Friend, Independent Director | ||
| Burkhard Prause, President and CEO, BEST | ||
| Christopher Ingen, Independent Director | ||
| Justin Ward, Senior Development | ||
| Rene Lenggenhager, President - Bruker BioSpin Group | ||
| Stacey Desrochers, Treasurer Relations | ||
| Brenda Furlong, Independent Director | ||
| Frank Laukien, Chairman, CEO and Pres | ||
| Richard Kniss, Independent Director | ||
| William Linton, Lead Independent Director | ||
| Gerald Herman, Interim CFO, Principal Accounting Officer | ||
| Joshua Young, Vice President of Investor Relations | ||
| Richard Packer, Independent Director | ||
| Robert Rosenthal, Director | ||
| Joerg Laukien, Director | ||
| Bernd Gewiese, Co-President of Bruker BioSpin Corporation | ||
| Werner Maas, Co-President of Bruker BioSpin Corporation |
Bruker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bruker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.34 | ||||
| Return On Asset | 0.077 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 12.08 B | ||||
| Shares Outstanding | 145.34 M | ||||
| Shares Owned By Insiders | 33.17 % | ||||
| Shares Owned By Institutions | 77.47 % | ||||
| Number Of Shares Shorted | 3.3 M | ||||
| Price To Earning | 67.10 X |
Pair Trading with Bruker
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bruker position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bruker will appreciate offsetting losses from the drop in the long position's value.Moving together with Bruker Stock
| 0.75 | DRRX | Durect Earnings Call This Week | PairCorr |
Moving against Bruker Stock
| 0.53 | SBFMW | Sunshine Biopharma | PairCorr |
| 0.53 | CUE | Cue Biopharma Buyout Trend | PairCorr |
| 0.47 | IPA | Immunoprecise Antibodies Financial Report 8th of July 2024 | PairCorr |
The ability to find closely correlated positions to Bruker could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bruker when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bruker - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bruker to buy it.
The correlation of Bruker is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bruker moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bruker moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bruker can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bruker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Bruker Stock, please use our How to Invest in Bruker guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Bruker Stock analysis
When running Bruker's price analysis, check to measure Bruker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bruker is operating at the current time. Most of Bruker's value examination focuses on studying past and present price action to predict the probability of Bruker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bruker's price. Additionally, you may evaluate how the addition of Bruker to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Bruker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bruker. If investors know Bruker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bruker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.127 | Dividend Share 0.2 | Earnings Share 2.9 | Revenue Per Share 20.249 | Quarterly Revenue Growth 0.206 |
The market value of Bruker is measured differently than its book value, which is the value of Bruker that is recorded on the company's balance sheet. Investors also form their own opinion of Bruker's value that differs from its market value or its book value, called intrinsic value, which is Bruker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bruker's market value can be influenced by many factors that don't directly affect Bruker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bruker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bruker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bruker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.